Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
NTRB

NTRB - Nutriband Inc. Stock Price, Fair Value and News

$4.66-0.31 (-6.24%)
Market Closed

11/100

NTRB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

11/100

NTRB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$3.84

Target 3M

$4.32

Target 6M

$4.08

NTRB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NTRB Price Action

Last 7 days

4.7%

Last 30 days

-16.3%

Last 90 days

-32.6%

Trailing 12 Months

-40.9%

NTRB RSI Chart

NTRB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NTRB Valuation

Market Cap

56.7M

Price/Earnings (Trailing)

-4.44

Price/Sales (Trailing)

24.9

EV/EBITDA

-4.1

Price/Free Cashflow

-10.05

NTRB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$3.84

Target 3M

$4.32

Target 6M

$4.08

NTRB Fundamentals

NTRB Revenue

Revenue (TTM)

2.3M

Rev. Growth (Yr)

-46.41%

Rev. Growth (Qtr)

-44.4%

NTRB Earnings

Earnings (TTM)

-12.8M

Earnings Growth (Yr)

-184.18%

Earnings Growth (Qtr)

-93.59%

NTRB Profitability

Operating Margin

33.50%

EBT Margin

-560.85%

Return on Equity

-169.27%

Return on Assets

-151.77%

Free Cashflow Yield

-9.95%

NTRB Investor Care

Shares Dilution (1Y)

9.62%

Diluted EPS (TTM)

-3.07

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20252.1M2.4M2.6M2.3M
20242.1M2.0M1.8M2.0M
20232.1M2.1M2.1M2.1M
20221.4M1.5M1.7M2.0M
2021943.7K1.3M1.4M1.3M
2020370.6K296.4K306.0K615.2K
2019245.3K276.6K308.0K339.3K
20180000
Get all data in R, Python etc through our Historical Stock Data APIs

About Nutriband Inc.

NTRB
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
0
 CEO
 WEBSITEhttps://nutriband.com
 SECTORHealthcare
 INDUSTRYBiotechnology

Nutriband Inc. Frequently Asked Questions

NTRB is the stock ticker symbol of Nutriband Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Nutriband Inc. is 56.73 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check NTRB's fair value in chart for subscribers.

The fair value guage provides a quick view whether NTRB is over valued or under valued. Whether Nutriband Inc. is cheap or expensive depends on the assumptions which impact Nutriband Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NTRB.

As of Wed Jan 28 2026, NTRB's PE ratio (Price to Earnings) is -4.44 and Price to Sales (PS) ratio is 24.9. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NTRB PE ratio will change depending on the future growth rate expectations of investors.